Literature DB >> 12203989

SNP databases and pharmacogenetics: great start, but a long way to go.

Sharon Marsh1, Pui Kwok, Howard L McLeod.   

Abstract

With the recent publication of the human genome project there has been an explosion of data available for pharmacogenetic research. Web-based databases containing information on single nucleotide polymorphisms (SNPs) are readily accessible to researchers, but there has been little comment on their utility. We used seven major international databases to identify SNPs in 74 genes involved in drug pathways. Very little overlap was seen among the databases, with only eight out of a putative 893 SNPs ( approximately 1%) common to the most commonly used databases. Problems with false positives, secondary to a high degree of homology in gene families, were also observed. These studies suggest researchers limiting their studies to one database would miss a great deal of information. Effort to update compilation databases, such as HGVbase, GeneSNP, PharmGKB, and HOWDY, and the aggressive removal of false positives from all databases is required if these resources are to facilitate the intended growth in pharmacogenetics research. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2002        PMID: 12203989     DOI: 10.1002/humu.10115

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  8 in total

1.  The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping.

Authors:  Andreas R Tobler; Sabine Short; Mark R Andersen; Teodoro M Paner; Jason C Briggs; Stephen M Lambert; Priscilla P Wu; Yiwen Wang; Alexander Y Spoonde; Ryan T Koehler; Nicolas Peyret; Caifu Chen; Adam J Broomer; Dana A Ridzon; Hui Zhou; Bradley S Hoo; Kathleen C Hayashibara; Lilley N Leong; Congcong N Ma; Barnet B Rosenblum; Joseph P Day; Janet S Ziegle; Francisco M De La Vega; Michael D Rhodes; Kevin M Hennessy; H Michael Wenz
Journal:  J Biomol Tech       Date:  2005-12

2.  The limits of genome-wide methods for pharmacogenomic testing.

Authors:  Eric R Gamazon; Andrew D Skol; Minoli A Perera
Journal:  Pharmacogenet Genomics       Date:  2012-04       Impact factor: 2.089

3.  Genotype and allele frequency of human multidrug resistance (MDR1) gene C3435T polymorphism in Denizli province of Turkey.

Authors:  Sebahat Turgut; Günfer Turgut; Erol Omer Atalay
Journal:  Mol Biol Rep       Date:  2006-11-02       Impact factor: 2.742

4.  UASIS: Universal Automatic SNP Identification System.

Authors:  Danny C C Poo; Shaojiang Cai; James T L Mah
Journal:  BMC Genomics       Date:  2011-11-30       Impact factor: 3.969

5.  Target SNP selection in complex disease association studies.

Authors:  Matthias Wjst
Journal:  BMC Bioinformatics       Date:  2004-07-12       Impact factor: 3.169

6.  Current limitations of SNP data from the public domain for studies of complex disorders: a test for ten candidate genes for obesity and osteoporosis.

Authors:  Volodymyr Dvornyk; Ji-Rong Long; Dong-Hai Xiong; Peng-Yuan Liu; Lan-Juan Zhao; Hui Shen; Yuan-Yuan Zhang; Yong-Jun Liu; Sonia Rocha-Sanchez; Peng Xiao; Robert R Recker; Hong-Wen Deng
Journal:  BMC Genet       Date:  2004-02-25       Impact factor: 2.797

Review 7.  Cancer pharmacogenetics.

Authors:  S Marsh; H L McLeod
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

8.  Full genotyping of a highly polymorphic human gene trait by time-resolved fluorescence resonance energy transfer.

Authors:  Edoardo Totè; Marco Lamperti; Maria Bondani; Domenico Salerno; Valeria Cassina; Luca Nardo
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.